Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.71 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.71 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.67 |
| ▸ | TGM2 | P21980 | 2/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGAV | P06756 | 1/20 | 0.59 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691897 | 0.97 | SIRT2 (0.67) | SIRT2SIRT1FOLH1TGM2SIRT3 | |
| SCHEMBL14357907 | 0.93 | SIRT2 (0.72) | SIRT2SIRT1FOLH1SIRT3CTSL | |
| SCHEMBL4561005 | 0.91 | FOLH1 (0.78) | SIRT2SIRT1FOLH1TGM2ITGB3 | |
| SCHEMBL806151 | 0.91 | FOLH1 (0.78) | SIRT2SIRT1FOLH1TGM2ITGB3 | |
| SCHEMBL464715 | 0.91 | FOLH1 (0.78) | SIRT2SIRT1FOLH1TGM2ITGB3 | |
| SCHEMBL20545282 | 0.89 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL20542673 | 0.89 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL20542671 | 0.89 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL20542972 | 0.89 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL4173691 | 0.87 | FOLH1 (0.72) | SIRT2SIRT1FOLH1TGM2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865935-B2 | Purification methods for betulonic acid and Boc-lysinated betulonic acid, and organic synthesis of betulonic acid amides with piperazine derivatives | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2014-10-21 | — | — | US | disclosed |
| US-20140243527-A1 | PURIFICATION METHODS FOR BETULONIC ACID AND BOC-LYSINATED BETULONIC ACID, AND ORGANIC SYNTHESIS OF BETULONIC ACID AMIDES WITH PIPERAZINE DERIVATIVES | KOREA INSTITUTE OF ENERGY RESEARCH (KR) | 2014-08-28 | — | — | US | disclosed |
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8008280-B2 | Betulinol derivatives as anti-HIV agents | BIORINGS LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | SAXENA RESEARCH, LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1786433-A4 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | SAXENA BRIJ B (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1802648-A2 | BETULINOL DERIVATIVES AS ANTI-CANCER AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1786433-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060154903-A1 | Betulinol derivatives as anti-cancer agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006031756-A2 | BETULINOL DERIVATIVES AS ANTI-CANCER AGENTS | CORNELL RESEARCH FOUNDATION, INC (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006031706-A2 | BETULINOL DERIVATIVES AS ANTI-HIV AGENTS | CORNELL RESEARCH FOUNDATION, INC (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | SIRT2 646/4885SIRT1 551/4885FOLH1 63/4885 |
| US-20060154903-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | SIRT2 611/4885SIRT1 639/4885FOLH1 70/4885 |
| US-20140243527-A1 | PURIFICATION METHODS FOR BETULONIC ACID AND BOC-LYSINATED BETULONIC ACID, AND ORGANIC SYNTHESIS OF BETULONIC ACID AMIDES WITH PIPERAZINE DERIVATIVES | BET1, LOX, BECN1 | SIRT2 1074/4885SIRT1 821/4885FOLH1 1059/4885 |
| US-20060154904-A1 | Betulinol derivatives as anti-HIV agents | BET1, NFATC1, CD4 | SIRT2 1065/4885SIRT1 834/4885FOLH1 2197/4885 |
| US-20080286291-A1 | Betulinol Derivatives as Anti-Hiv Agents | BET1, NFATC1, CD4 | SIRT2 1065/4885SIRT1 834/4885FOLH1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.